Medifast Inc has a consensus price target of $85.67, established from looking at the 13 latest analyst ratings. The last 3 analyst ratings were released from DA Davidson, DA Davidson, and Stephens & Co. on April 30, 2024, February 21, 2024, and October 13, 2023. With an average price target of $49 between DA Davidson, DA Davidson, and Stephens & Co., there's an implied 85.33% upside for Medifast Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on April 30, 2024. The analyst firm set a price target for $25.00 expecting MED to fall to within 12 months (a possible -5.45% downside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast maintained their neutral rating.
There is no last upgrade for Medifast.
The last downgrade for Medifast Inc happened on November 4, 2022 when DA Davidson changed their price target from $278 to $106 for Medifast Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $40.00 to $25.00. The current price Medifast (MED) is trading at is $26.44, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.